Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The SURVET Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial -

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The SURVET Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial
Information type: Randomised controlled trials
Source: Circulation Research
Specialities: Cardiovascular system disorders
Summary
In this study, the use of sulodexide following discontinuation of anticoagulant therapy in patients with a first unprovoked VTE reduced the incidence of VTE recurrence (15/307 versus 30/308 with placebo; HR 0.49, 95% CI 0.27-0.92; P=0.025); adverse events were similar.
UKMi comment
Sulodexide is a heparinoid consisting of a mixture of low-molecular-weight heparin and dermatan sulfate. It is used as a hypolipidaemic and antithrombotic and has been given orally and parenterally for peripheral vascular disease and cerebrovascular disease. It is also included in preparations used topically for local vascular inflammation and soft-tissue disorders.

Sulodexide is not licensed in the UK.
Related links: Editorial